BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol 2017;13:548-60. [PMID: 28769114 DOI: 10.1038/nrrheum.2017.124] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
Number Citing Articles
1 Udry S, Latino JO, Belizna C, Perés Wingeyer S, Fernández Romero DS, de Larrañaga G. A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunol Res 2019;67:478-85. [PMID: 31873844 DOI: 10.1007/s12026-019-09110-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs 2021. [PMID: 34904182 DOI: 10.1007/s40272-021-00484-w] [Reference Citation Analysis]
3 Serrano M, Espinosa G, Serrano A, Cervera R. Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. Int J Mol Sci 2022;23:4946. [PMID: 35563337 DOI: 10.3390/ijms23094946] [Reference Citation Analysis]
4 Ramirez GA, Efthymiou M, Isenberg DA, Cohen H. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology 2019;58:940-52. [DOI: 10.1093/rheumatology/key307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
5 Serrano M, Morán L, Martinez-Flores JA, Mancebo E, Pleguezuelo D, Cabrera-Marante O, Delgado J, Serrano A. Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation. Front Immunol 2019;10:2891. [PMID: 31921152 DOI: 10.3389/fimmu.2019.02891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Dieudonné Y, Guffroy A, Poindron V, Sprauel PS, Martin T, Korganow AS, Gies V. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmun Rev 2021;20:102798. [PMID: 33722752 DOI: 10.1016/j.autrev.2021.102798] [Reference Citation Analysis]
7 Cheldieva FA, Reshetnyak TM, Cherkasova MV, Lila AM. Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). Klin Lab Diagn 2021;66:546-51. [PMID: 34543533 DOI: 10.51620/0869-2084-2021-66-9-546-551] [Reference Citation Analysis]
8 Sciascia S, Radin M, Cecchi I, Fenoglio R, De Marchi A, Besso L, Baldovino S, Rossi D, Miraglia P, Rubini E, Roccatello D. Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol 2020;33:757-62. [PMID: 31974856 DOI: 10.1007/s40620-019-00698-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Uludağ Ö, Çene E, Gurel E, Çetin Ç, Bektaş M, Yalçınkaya Y, Diz-Küçükkaya R, Gül A, Inanç M, Artim-Esen B. Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus 2022;:9612033221079781. [PMID: 35166607 DOI: 10.1177/09612033221079781] [Reference Citation Analysis]
10 Sciascia S, Radin M, Ramirez C, Seaman A, Bentow C, Casas S, Cecchi I, Rubini E, Foddai SG, Baldovino S, Fenoglio R, Menegatti E, Roccatello D, Mahler M. Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmun Rev 2020;19:102641. [PMID: 32801044 DOI: 10.1016/j.autrev.2020.102641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rosina S, Chighizola CB, Ravelli A, Cimaz R. Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Curr Rheumatol Rep 2021;23:10. [PMID: 33511497 DOI: 10.1007/s11926-020-00976-7] [Reference Citation Analysis]
12 Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep 2022;23:85. [PMID: 34985614 DOI: 10.1007/s11926-021-01038-2] [Reference Citation Analysis]
13 Harifi G, Nour-Eldine W, Noureldine MHA, Berjaoui MB, Kallas R, Khoury R, Uthman I, Al-Saleh J, Khamashta MA. Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. Autoimmun Rev 2018;17:256-66. [PMID: 29339317 DOI: 10.1016/j.autrev.2017.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Serrano M, Espinosa G, Lalueza A, Bravo-Gallego LY, Diaz-Simón R, Garcinuño S, Gil-Etayo J, Moises J, Naranjo L, Prieto-González S, Ruiz-Ortiz E, Sánchez B, Moreno-Castaño AB, Díaz-Pedroche C, Viñas-Gomis O, Cervera R, Serrano A; APS-COVID 19 Study Group/European Forum on Antiphospholipid Antibodies. Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019. ACR Open Rheumatol 2021;3:267-76. [PMID: 33738987 DOI: 10.1002/acr2.11245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Misasi R, Longo A, Recalchi S, Caissutti D, Riitano G, Manganelli V, Garofalo T, Sorice M, Capozzi A. Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS". Int J Mol Sci 2020;21:E8411. [PMID: 33182499 DOI: 10.3390/ijms21218411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Shapira Y, Ben-Arie-Weintrob Y, Gilburd B, Reuter S, Sánchez-Castañón M, López-Hoyos M, Agmon-Levin N. Antiphospholipid antibodies may be associated with uveitis. Eur J Ophthalmol 2020;:1120672120968729. [PMID: 33148033 DOI: 10.1177/1120672120968729] [Reference Citation Analysis]
17 Maher L, Perugino C. Diagnostic Pitfalls in Immunology Testing. Clinics in Laboratory Medicine 2019;39:567-78. [DOI: 10.1016/j.cll.2019.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Serrano R, Pons-Estel GJ, Espinosa G, Quintana RM, Reverter JC, Tassies D, Monteagudo J, Cervera R. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. Lupus 2020;29:1050-9. [PMID: 32536318 DOI: 10.1177/0961203320933009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Gil-Etayo FJ, Garcinuño S, Lalueza A, Díaz-Simón R, García-Reyne A, Pleguezuelo DE, Cabrera-Marante O, Rodriguez-Frias EA, Perez-Rivilla A, Serrano M, Serrano A. Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor. Biomedicines 2021;9:899. [PMID: 34440103 DOI: 10.3390/biomedicines9080899] [Reference Citation Analysis]
20 Noureldine MHA, Nour-Eldine W, Khamashta MA, Uthman I. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. Semin Arthritis Rheum 2019;48:860-6. [PMID: 30217394 DOI: 10.1016/j.semarthrit.2018.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
21 Radin M, Cecchi I, Foddai SG, Rubini E, Barinotti A, Ramirez C, Seaman A, Roccatello D, Mahler M, Sciascia S. Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies. Biomedicines 2020;8:E622. [PMID: 33348782 DOI: 10.3390/biomedicines8120622] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Appelgren D, Dahle C, Knopf J, Bilyy R, Vovk V, Sundgren PC, Bengtsson AA, Wetterö J, Muñoz LE, Herrmann M, Höög A, Sjöwall C. Active NET formation in Libman–Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. Autoimmunity 2018;51:310-8. [DOI: 10.1080/08916934.2018.1514496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Zhang J, Li C, Han X, Chen Z, Adhikari BK, Wang Y, Wang Y, Sun J. The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies. Ann Med 2021;53:1328-39. [PMID: 34409894 DOI: 10.1080/07853890.2021.1962964] [Reference Citation Analysis]
24 Nikolopoulos D, Adamichou C, Bertsias G. Suspected systemic rheumatic diseases in patients presenting with cytopenias. Best Practice & Research Clinical Rheumatology 2019;33:101425. [DOI: 10.1016/j.berh.2019.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wei M, Xu Y, Xia D, Li J, Dong S. Care and Treatment for an Antiphospholipid Syndrome-Related Lower Limb Skin Ulcer Unhealed for 7 Years: A Case Report. Int J Low Extrem Wounds 2022;:15347346221090079. [PMID: 35360964 DOI: 10.1177/15347346221090079] [Reference Citation Analysis]
26 Zou X, Fan Z, Zhao L, Xu W, Zhang J, Jiang Z. Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome. BMC Gastroenterol 2021;21:148. [PMID: 33794795 DOI: 10.1186/s12876-021-01736-2] [Reference Citation Analysis]
27 Cecchi I, Radin M, Rubini E, Foddai SG, Barinotti A, Roccatello D, Sciascia S. Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. Lupus 2021;30:884-92. [PMID: 33593163 DOI: 10.1177/0961203321995248] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? Nat Rev Rheumatol 2018;14:433-40. [PMID: 29891914 DOI: 10.1038/s41584-018-0032-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
29 Navarro CE, Arango GJ, Cubides MF. Chronic relapsing inflammatory optic neuropathy in a patient with triple antiphospholipid antibody positivity. Neurol Sci 2021;42:3439-43. [PMID: 33880676 DOI: 10.1007/s10072-021-05263-6] [Reference Citation Analysis]
30 Araújo DM, Rodrigues CEM, Gonçalves NGG, Rabelo-Júnior CN, Lobo MDP, Moreira RA, Monteiro-Moreira ACO. Proteins Involved in the Induction of Procoagulant Activity and Autoimmune Response in Patients With Primary Antiphospholipid Syndrome. Clin Appl Thromb Hemost 2020;26:1076029620905338. [PMID: 32299226 DOI: 10.1177/1076029620905338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis 2019;78:155-61. [PMID: 30282668 DOI: 10.1136/annrheumdis-2018-213846] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
32 Conti F, Andreoli L, Crisafulli F, Mancuso S, Truglia S, Tektonidou MG. Does seronegative obstetric APS exist? "pro" and "cons". Autoimmun Rev 2019;18:102407. [PMID: 31639518 DOI: 10.1016/j.autrev.2019.102407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
33 Scheen M, Adedjouma A, Esteve E, Buob D, Abisror N, Planche V, Fain O, Boffa JJ, De Seigneux S, Mekinian A, Haidar F. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev 2022;:103072. [PMID: 35217200 DOI: 10.1016/j.autrev.2022.103072] [Reference Citation Analysis]
34 Thaler MA, Bietenbeck A, Steigerwald U, Büttner T, Schierack P, Lindhoff-Last E, Roggenbuck D, Luppa PB. Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS One 2019;14:e0220033. [PMID: 31339913 DOI: 10.1371/journal.pone.0220033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
35 Franco AMM, Medina FMC, Balbi GGM, Levy RA, Signorelli F. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. Lupus 2020;29:1528-43. [PMID: 32814509 DOI: 10.1177/0961203320949667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hughes GRV, Khamashta MA. 'Seronegative antiphospholipid syndrome': an update. Lupus 2019;28:273-4. [PMID: 30691344 DOI: 10.1177/0961203319826358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
37 Schofield JR, Hughes HN, Birlea M, Hassell KL. A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients. Lupus 2021;30:568-77. [PMID: 33402037 DOI: 10.1177/0961203320983913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Naranjo L, Ostos F, Gil-Etayo FJ, Hernández-Gallego J, Cabrera-Marante Ó, Pleguezuelo DE, Díaz-Simón R, Cerro M, Lora D, Martínez-Salio A, Serrano A. Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke. Front Cardiovasc Med 2021;8:665741. [PMID: 34012984 DOI: 10.3389/fcvm.2021.665741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Cabrera-Marante O, Rodríguez de Frías E, Serrano M, Lozano Morillo F, Naranjo L, Gil-Etayo FJ, Paz-Artal E, Pleguezuelo DE, Serrano A. The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int J Mol Sci 2020;21:E8972. [PMID: 33255963 DOI: 10.3390/ijms21238972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Chen YL, Yang HT, Liu LX, Chen CH, Huang Q, Hong XP, Zhao JL, Liu DZ. Dorsolateral medullary infarction during skin infection by Stenotrophomonas maltophilia in a patient with triple antiphospholipid antibody positivity: a case-based review. Clin Rheumatol 2021;40:2965-71. [PMID: 33155156 DOI: 10.1007/s10067-020-05489-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Truglia S, Capozzi A, Mancuso S, Recalchi S, Spinelli FR, Perricone C, De Carolis C, Manganelli V, Riitano G, Garofalo T, Longo A, De Carolis S, Alessandri C, Misasi R, Valesini G, Sorice M, Conti F. A Monocentric Cohort of Obstetric Seronegative Anti-Phospholipid Syndrome. Front Immunol 2018;9:1678. [PMID: 30079071 DOI: 10.3389/fimmu.2018.01678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
42 Sciascia S, Radin M, Cecchi I, Rubini E, Scotta A, Rolla R, Montaruli B, Pergolini P, Mengozzi G, Muccini E, Baldovino S, Ferro M, Vaccarino A, Mahler M, Menegatti E, Roccatello D. Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. Front Immunol 2019;10:376. [PMID: 30891041 DOI: 10.3389/fimmu.2019.00376] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
43 Pérez D, Stojanovich L, Naranjo L, Stanisavljevic N, Bogdanovic G, Serrano M, Serrano A. Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome. Front Immunol 2018;9:2644. [PMID: 30524428 DOI: 10.3389/fimmu.2018.02644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
44 Petri M. Antiphospholipid syndrome. Transl Res 2020;225:70-81. [PMID: 32413497 DOI: 10.1016/j.trsl.2020.04.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
45 Pleguezuelo DE, Cabrera-Marante O, Abad M, Rodriguez-Frias EA, Naranjo L, Vazquez A, Villar O, Gil-Etayo FJ, Serrano M, Perez-Rivilla A, de la Fuente-Bitaine L, Serrano A. Anti-Phosphatidylserine/Prothrombin Antibodies in Healthy Women with Unexplained Recurrent Pregnancy Loss. J Clin Med 2021;10:2094. [PMID: 34068095 DOI: 10.3390/jcm10102094] [Reference Citation Analysis]
46 Hanly JG, Inanç M. The neurology of lupus. J Neurol Sci 2021;424:117419. [PMID: 33832774 DOI: 10.1016/j.jns.2021.117419] [Reference Citation Analysis]
47 Ortel TL, Meleth S, Catellier D, Crowther M, Erkan D, Fortin PR, Garcia D, Haywood N, Kosinski AS, Levine SR, Phillips MJ, Whitehead N. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. J Thromb Haemost 2020;18:2274-86. [PMID: 32484606 DOI: 10.1111/jth.14936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
48 Radin M, Foddai SG, Barinotti A, Cecchi I, Rubini E, Sciascia S, Roccatello D. Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. Orphanet J Rare Dis 2021;16:280. [PMID: 34134750 DOI: 10.1186/s13023-021-01906-1] [Reference Citation Analysis]
49 Islabão AG, Mota LMH, Ribeiro MCM, Arabi TM, Cividatti GN, Queiroz LB, Andrade DC, Sakamoto AP, Trindade VC, Novak GV, Molinari BC, Campos LM, Aikawa NE, Pereira RMR, Terreri MT, Magalhães CS, Marini R, Gomes HR, Silva MF, Oliveira SK, Sztajnbok FR, Sacchetti SB, Bica BE, Sena EG, Moraes AP, Santos MC, Robazzi TC, Spelling PF, Scheibel IM, Cavalcanti AS, Naka EN, Guimarães LJ, Santos FP, Sampaio MC, Bonfá E, Silva CA; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients. Autoimmun Rev 2020;19:102693. [PMID: 33164791 DOI: 10.1016/j.autrev.2020.102693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Pires da Rosa G, Bettencourt P, Rodríguez-Pintó I, Cervera R, Espinosa G. "Non-criteria" antiphospholipid syndrome: A nomenclature proposal. Autoimmun Rev 2020;19:102689. [PMID: 33223008 DOI: 10.1016/j.autrev.2020.102689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, Belizna C, Ruffatti A, Hoxha A, Tincani A, Nalli C, Marozio L, Maina A, Espinosa G, Ríos-Garcés R, Cervera R, Carolis S, Monteleone G, Latino O, Udry S, LLurba E, Garrido-Gimenez C, Trespidi L, Gerosa M, Chighizola CB, Rovere-Querini P, Canti V, Mayer-Pickel K, Tabacco S, Arnau A, Trapé J, Ruiz-Hidalgo D, Sos L, Farran-Codina I; EUROAPS Study Group. Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology (Oxford) 2020;59:1306-14. [PMID: 31580459 DOI: 10.1093/rheumatology/kez419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
52 Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol 2019;206:53-62. [PMID: 29510235 DOI: 10.1016/j.clim.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum 2018;48:117-20. [PMID: 29395258 DOI: 10.1016/j.semarthrit.2017.12.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
54 Morales JM, Serrano M, Martinez-flores JA, Perez D, Serrano A. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation 2019;103:481-6. [DOI: 10.1097/tp.0000000000002510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
55 Serrano A, Cervera R, Gris JC. Editorial: Primary Antiphospholipid Syndrome. Front Immunol 2020;11:1993. [PMID: 32983139 DOI: 10.3389/fimmu.2020.01993] [Reference Citation Analysis]
56 Cecchi I, Radin M, Rodríguez-Carrio J, Tambralli A, Knight JS, Sciascia S. Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. Expert Rev Clin Immunol 2021;17:395-406. [PMID: 33686921 DOI: 10.1080/1744666X.2021.1901581] [Reference Citation Analysis]
57 Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. J Clin Med 2021;10:4427. [PMID: 34640445 DOI: 10.3390/jcm10194427] [Reference Citation Analysis]
58 Torres-jimenez A, Ramirez-nova V, Cespedes-cruz AI, Sanchez-jara B, Velazquez-cruz A, Bekker-méndez VC, Guerra-castillo FX. Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. Pediatr Rheumatol 2022;20. [DOI: 10.1186/s12969-022-00673-y] [Reference Citation Analysis]
59 ValdÉs Corona LF, DÍaz BorjÓn A. Mononeuritis Multiplex Associated With Antiphospholipid Antibodies. Arch Rheumatol 2020;35:146-8. [PMID: 32637932 DOI: 10.5606/ArchRheumatol.2020.7604] [Reference Citation Analysis]
60 Sciascia S, Radin M, Cecchi I, Bertolaccini ML, Bertero MT, Rubini E, Vaccarino A, Bazzan M, Giachino O, Baldovino S, Rossi D, Mengozzi G, Roccatello D. Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology (Oxford) 2021;60:1106-13. [PMID: 31840749 DOI: 10.1093/rheumatology/kez596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Menozzi E, Mulroy E, Akbarian-Tefaghi L, Bhatia KP, Balint B. Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations. Parkinsonism Relat Disord 2021;88:116-28. [PMID: 34092506 DOI: 10.1016/j.parkreldis.2021.05.026] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Sciascia S, Radin M, Cecchi I, Rubini E, Bazzan M, Roccatello D. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Seminars in Arthritis and Rheumatism 2019;48:741-4. [DOI: 10.1016/j.semarthrit.2018.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Tang KT, Wu TY, Chen HH, Lin CC, Hsu YH. Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation-Mechanisms analyzed using hydrogen/deuterium exchange. Protein Sci 2021;30:927-39. [PMID: 33641242 DOI: 10.1002/pro.4054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Medina G, Cimé-Aké E, Bonilla-Vázquez R, Vera-Lastra O, Saavedra MÁ, Cruz-Domínguez MP, Jara LJ. Disability and cognitive impairment are interdependent in primary antiphospholipid syndrome. Lupus 2022;:9612033221106647. [PMID: 35657275 DOI: 10.1177/09612033221106647] [Reference Citation Analysis]
65 Barinotti A, Radin M, Cecchi I, Foddai SG, Rubini E, Roccatello D, Sciascia S, Menegatti E. Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. Int J Mol Sci 2020;21:E9551. [PMID: 33333988 DOI: 10.3390/ijms21249551] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Sciascia S, Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Vaccarino A, Rossi D, Roccatello D. Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. Front Med (Lausanne) 2021;8:621590. [PMID: 33598471 DOI: 10.3389/fmed.2021.621590] [Reference Citation Analysis]
67 Miyamae T, Kawabe T. Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome. J Clin Med 2021;10:1240. [PMID: 33802787 DOI: 10.3390/jcm10061240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Salle V. [Seronegative antiphospholipid syndrome: Myth or reality?]. Rev Med Interne 2020;41:265-74. [PMID: 32115196 DOI: 10.1016/j.revmed.2020.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Djokovic A, Stojanovich L, Stanisavljevic N, Djokic S, Filipovic B, Matic P, Milanovic M, Apostolovic S, Saponjski J. Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort. Clin Rheumatol 2022. [PMID: 35018582 DOI: 10.1007/s10067-022-06056-8] [Reference Citation Analysis]
70 Abe N, Oku K, Amengual O, Fujieda Y, Kato M, Bohgaki T, Yasuda S, Mori R, Morishita E, Suzuki-inoue K, Atsumi T. Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. Modern Rheumatology 2020;30:116-24. [DOI: 10.1080/14397595.2018.1558934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
71 Vlagea A, Pascual-Salcedo D, Álvarez Doforno R, Lavilla P, Diez J, Padilla Merlano B, Cuesta MV, Gil A. IgA anti-β2 glycoprotein I antibodies: Experience from a large center. Thromb Res 2018;162:38-43. [PMID: 29274563 DOI: 10.1016/j.thromres.2017.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]